Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes

Neuroscience
K TieuP H Yu

Abstract

The neurotoxin 6-hydroxydopamine has been used to induce selective dopaminergic cell death in animal models of Parkinson's disease. The response of neurons to this toxin has been shown to be greatly influenced by astrocytes. Our laboratory reported previously that human neuroblastoma SH-SY5Y cells became more resistant to the toxicity of 6-hydroxydopamine when co-cultured with mouse astrocytes. This enhanced tolerance required direct and specific adhesion between SH-SY5Y cells and astrocytes. We hypothesized that this interaction led to biochemical changes in SH-SY5Y cells, thereby protecting these cells from toxicity. To study these changes, we again co-cultured SH-SY5Y cells with astrocytes and treated them with 6-hydroxydopamine. An optimized condition of trypsin treatment was employed to separate SH-SY5Y cells from astrocytes quickly. Western blot analysis demonstrated that 6-hydroxydopamine significantly increased p53 protein in monolayer SH-SY5Y cells grown in either regular medium or conditioned medium from astrocytes. This change, however, was not observed in the group co-cultured with astrocytes. Data obtained from the ribonuclease protection assay indicated that similar changes also occurred at the transcriptional lev...Continue Reading

References

Jul 2, 1992·Nature·D P Lane
Jul 5, 1991·Science·M HollsteinC C Harris
Dec 20, 1990·Nature·B Vogelstein
Jan 1, 1986·Annals of the New York Academy of Sciences·R K Orkand
Oct 6, 1987·Brain Research·S VibulsrethR Busto
Jan 15, 1986·Brain Research·M TytellR J Lasek
Feb 1, 1970·Journal of Neurochemistry·N J Uretsky, L L Iversen
Dec 1, 1968·European Journal of Pharmacology·U Ungerstedt
Aug 15, 1984·The Biochemical Journal·T F Slater
Jan 15, 1982·Biochemical Pharmacology·E Tiffany-CastiglioniJ R Perez-Polo
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·U M MollG Riou
Apr 1, 1993·Journal of Neuroscience Methods·J B SassB H Juurlink
Mar 1, 1996·Molecular and Cellular Biology·U M MollG Zambetti
Dec 15, 1995·Brain Research·D M BronsteinM K McMillian
Jun 1, 1996·Progress in Neurobiology·A Vernadakis
May 29, 1998·Journal of Neurochemistry·E E OchuC M Waters
Jun 12, 1998·The Journal of Comparative Neurology·R A ShellerG D Bittner
Jan 16, 1999·Brain Research. Molecular Brain Research·R C DodelS M Paul

❮ Previous
Next ❯

Citations

Apr 7, 2004·Proceedings of the National Academy of Sciences of the United States of America·Motoyuki HirasawaAshok B Kulkarni
Jul 24, 2008·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Steven J MullettDavid A Hinkle
Aug 10, 2013·Cancer Medicine·Shuko HataHironobu Sasano
Nov 10, 2009·Journal of Neurochemistry·Christopher M DavenportJennifer M Pocock
Dec 5, 2015·The Journal of Physiology·Eric HillMichael Coleman
Sep 28, 2005·Neurochemical Research·Subhas C BiswasLloyd A Greene

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.